Thereof, designing targeted therapies that can enhance the levels of ROS and impede glioma proliferation via inhibition of PI3K/AKT/mTOR pathway are vitally important as they might improve glioma patient therapeutic outcome (Taylor et al., 2019). The gene discussed is MTOR; the disease is central nervous system cancer.